Nona and Umoja Collaborate on Innovative CAR-T Cell Therapies

Friday, 13 September 2024, 08:34

CAR-T cell therapies are being advanced through a collaboration between Nona Biosciences and Umoja Biopharma. This multi-target antibody discovery aims to develop off-the-shelf CAR-T cell treatments, leveraging Nona’s fully human heavy chain only antibody technology. The partnership is poised to significantly impact the future of cancer treatments.
LivaRava_Medicine_Default.png
Nona and Umoja Collaborate on Innovative CAR-T Cell Therapies

Partnership Overview

Nona Biosciences and Umoja Biopharma have officially announced a groundbreaking collaboration aimed at enhancing CART cell therapies. This strategic partnership focuses on a multi-target antibody discovery initiative.

Key Features of the Collaboration

  • Development of off-the-shelf CAR-T therapies.
  • Utilization of Nona’s fully human heavy chain only antibody (HCAb) technology.
  • Focus on multi-target approaches to improve treatment efficacy.

Potential Impact on Cancer Treatment

This collaboration is expected to significantly enhance treatment options for patients, providing innovative solutions within oncology.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe